Update on the Use of Biologic Therapy in Ulcerative Colitis

Overview

Journal Curr Treat Options Gastroenterol

Specialty Gastroenterology

Date 2017 Jan 26

PMID 28120279

Citations 11

Authors

Aakash Aggarwal

Timothy Sabol

Haleh Vaziri

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a major form of inflammatory bowel disease and is characterized by chronic inflammation of the colon and rectum and by alternating periods of flares and remissions. Symptoms may include rectal bleeding, abdominal pain, and diarrhea. The pathogenesis of UC is complex and involves a combination of immune dysregulation, genetics, environmental factors, and microbiota. The goal of medical treatment is to induce and maintain remission. Traditionally, the treatment options for UC included 5-aminosalicylates, corticosteroids, and immunomodulators. However, over the past decade, with the approval of various biologic agents for treatment of UC, the management of UC has been revolutionized. Currently, the FDA-approved biologics for treatment of UC include infliximab, adalimumab, golimumab, and vedolizumab. There are a number of other agents which are under investigation and may become available soon as treatment options for UC. The purpose of this article is to provide a summary of various biologics in the treatment of UC.

Citing Articles

Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.

Clemow D, Radawski C, Milata J, Alaka K, Hunter Gibble T, Schaum A Crohns Colitis 360. 2024; 6(4):otae054.

PMID: 39473630 PMC: 11520749. DOI: 10.1093/crocol/otae054.

Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.

Reinisch W, Melmed G, Nakase H, Seidelin J, Ma C, Xuan S Adv Ther. 2024; 41(10):3832-3849.

PMID: 39126596 PMC: 11399208. DOI: 10.1007/s12325-024-02912-y.

Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis.

Lee S, Betts K, Du E, Nie X, Gupte-Singh K, Ritter T Crohns Colitis 360. 2024; 6(2):otae026.

PMID: 38751576 PMC: 11094759. DOI: 10.1093/crocol/otae026.

Targeted modulation of intestinal epithelial regeneration and immune response in ulcerative colitis using dual-targeting bilirubin nanoparticles.

Zhuo Z, Guo K, Luo Y, Yang Q, Wu H, Zeng R Theranostics. 2024; 14(2):528-546.

PMID: 38169633 PMC: 10758062. DOI: 10.7150/thno.87739.

Self-Double-Emulsifying Drug Delivery System Enteric-Coated Capsules: A Novel Approach to Improve Oral Bioavailability and Anti-inflammatory Activity of Panax notoginseng Saponins.

Wang Y, Shang Y, Tang F, Qiu K, Wei X, Wang Z AAPS PharmSciTech. 2023; 24(4):90.

PMID: 36977927 DOI: 10.1208/s12249-023-02549-0.

References

Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J . Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012; 380(9857):1909-15. DOI: 10.1016/S0140-6736(12)61084-8. View

Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

Panaccione R, Ghosh S, Middleton S, Marquez J, Scott B, Flint L . Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146(2):392-400.e3. DOI: 10.1053/j.gastro.2013.10.052. View

Papadakis K, Targan S . Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98. DOI: 10.1146/annurev.med.51.1.289. View

Engel T, Kopylov U . Ustekinumab in Crohn's disease: evidence to date and place in therapy. Ther Adv Chronic Dis. 2016; 7(4):208-14. PMC: 4935835. DOI: 10.1177/2040622316653306. View

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

Soler D, Chapman T, Yang L, Wyant T, Egan R, Fedyk E . The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009; 330(3):864-75. DOI: 10.1124/jpet.109.153973. View

Yamada S, Yoshino T, Matsuura M, Minami N, Toyonaga T, Honzawa Y . Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol. 2014; 14:80. PMC: 4012244. DOI: 10.1186/1471-230X-14-80. View

Dalal S, Cohen R . What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. Gastroenterol Hepatol (N Y). 2016; 11(10):657-65. PMC: 4849518. View

10.

Ochsenkuhn T, Sackmann M, Goke B . Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004; 16(11):1167-71. DOI: 10.1097/00042737-200411000-00014. View

11.

Wasan S, Baker S, Skolnik P, Farraye F . A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010; 105(6):1231-8. DOI: 10.1038/ajg.2009.733. View

12.

Gibson D, Heetun Z, Redmond C, Nanda K, Keegan D, Byrne K . An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2014; 13(2):330-335.e1. DOI: 10.1016/j.cgh.2014.07.041. View

13.

Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

14.

Filippi J, Laharie D, Michiels C, Flamand M, Bouguen G, Nancey S . Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. J Crohns Colitis. 2015; 9(3):252-8. DOI: 10.1093/ecco-jcc/jjv001. View

15.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

16.

Murch S, Lamkin V, Savage M, Walker-Smith J, MacDonald T . Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991; 32(8):913-7. PMC: 1378961. DOI: 10.1136/gut.32.8.913. View

17.

Gibson P, Feagan B, Sandborn W, Marano C, Strauss R, Johanns J . Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016; 7:e168. PMC: 4855165. DOI: 10.1038/ctg.2016.24. View

18.

Shealy D, Cai A, Staquet K, Baker A, Lacy E, Johns L . Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010; 2(4):428-39. PMC: 3180089. DOI: 10.4161/mabs.12304. View

19.

Narula N, Marshall J, Colombel J, Leontiadis G, Williams J, Muqtadir Z . Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016; 111(4):477-91. DOI: 10.1038/ajg.2016.7. View

20.

Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-76. DOI: 10.1056/NEJMoa050516. View